LivaNova PLC
Description
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
About
CEO
Mr. Vladimir A. Makatsaria
Employees
2,900
Instrument type
Common Stock
Sector
Healthcare
Industry
Medical Devices
MIC code
XNGS
Address
20 Eastbourne Terrace, London, W2 6LG, United Kingdom
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Oct 28, 2025 | — | — | — | — |
| Jul 29, 2025 | — | — | — | — |
| Apr 29, 2025 | — | — | — | — |
| Feb 19, 2025 | 0.81 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 7 | — | 10 |
| Average estimate | — | 0.79 | — | 3.63 |
| Low estimate | — | 0.73 | — | 3.36 |
| High estimate | — | 0.83 | — | 3.78 |
| Last year EPS | — | 0.73 | — | 3.33 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-7.980%
Next qtr. (Mar 2025)
7.950%
Current year
19.070%
Next year (Dec 2025)
8.970%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 1.15B | 1.02B | 1.04B | 934.24M | 1.08B |
| Cost of revenue | 382.30M | 314.58M | 329.37M | 339.48M | 360.37M |
| Gross profit | 771.25M | 707.23M | 705.99M | 594.76M | 723.81M |
| Operating expense | |||||
| Research & development | 193.82M | 155.81M | 183.41M | 152.90M | 146.85M |
| Selling general and admin | 518.13M | 469.24M | 471.90M | 446.56M | 528.47M |
| Other operating expenses | 37.83M | 29.54M | 51.46M | 67.77M | 35.11M |
| Operating income | 21.48M | 52.64M | -784,000 | -72.47M | 13.38M |
| Non operating interest income | |||||
| Income | 22.01M | 4.70M | 435,000 | 131,000 | 803,000 |
| Expense | 58.85M | 48.25M | 50.15M | 40.84M | 15.09M |
| Other income expense | -65.86M | -84.23M | -73.97M | -232.36M | -187.47M |
| Pretax income | -81.23M | -75.14M | -124.47M | -348.02M | -188.38M |
| Tax provision | -98.88M | 11.05M | 11.20M | -960,000 | -30.37M |
| Net income | 17.55M | -86.25M | -135.82M | -348.82M | -157.64M |
| Basic EPS | 0.33 | -1.61 | -2.68 | -7.10 | -3.21 |
| Diluted EPS | 0.32 | -1.61 | -2.68 | -7.10 | -3.21 |
| Basic average shares | 53.90M | 53.50M | 50.60M | 48.60M | 48.30M |
| Diluted average shares | 53.90M | 53.50M | 50.60M | 48.60M | 48.30M |
| EBITDA | 103.41M | 115.83M | 68.42M | 3.71M | 95.21M |
| Net income from continuing op. | 17.55M | -86.25M | -135.82M | -348.82M | -157.64M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 2.43B | 2.29B | 2.20B | 2.40B | 2.41B |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 266.50M | 214.17M | 207.99M | 252.83M | 61.14M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 215.07M | 183.11M | 185.35M | 184.36M | 257.77M |
| Other receivables | — | — | — | — | — |
| Inventory | 147.89M | 129.38M | 105.84M | 115.29M | 164.15M |
| Prepaid assets | — | 31.71M | 37.62M | 60.24M | 37.78M |
| Restricted cash | 311.37M | 301.45M | — | — | — |
| Assets held for sale | — | — | — | 70.54M | — |
| Hedging assets | — | 1.33M | 106.63M | 2.05M | — |
| Other current assets | 27.18M | 26.32M | 35.75M | 22.74M | 28.60M |
| Non current assets | |||||
| Properties | 57.54M | 44.69M | 49.85M | 59.92M | 63.80M |
| Land and improvements | 14.90M | 14.64M | 15.10M | 15.75M | 15.17M |
| Machinery furniture equipment | 233.34M | 206.89M | 195.92M | 200.70M | 205.71M |
| Construction in progress | 10.75M | 11.31M | 12.11M | 19.53M | 18.22M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -196.04M | -175.12M | -161.79M | -158.62M | -153.99M |
| Goodwill | 1.83B | 1.91B | 2.20B | 2.28B | 2.44B |
| Investment properties | — | — | — | — | — |
| Financial assets | 38.50M | 54.39M | — | 72.30M | — |
| Intangible assets | 261.18M | 368.56M | 399.68M | 437.64M | 607.55M |
| Investments and advances | 22.84M | 16.27M | 16.60M | 31.09M | 27.26M |
| Other non current assets | 130.92M | 17.62M | 15.30M | 14.24M | 76.03M |
| Total liabilities | 1.15B | 1.09B | 906.31M | 1.29B | 1.03B |
| Current liabilities | |||||
| Accounts payable | 80.85M | 74.31M | 68.00M | 73.67M | 85.89M |
| Accrued expenses | 79.87M | 54.31M | 55.30M | 66.77M | 78.94M |
| Short term debt | 26.47M | 32.81M | 240.93M | 24.62M | 88.51M |
| Deferred revenue | 10.73M | 10.23M | 8.42M | 6.93M | 6.73M |
| Tax payable | 23.34M | 16.51M | 15.14M | 16.46M | 12.72M |
| Pensions | 94.63M | 72.19M | 79.27M | 51.88M | 70.42M |
| Other current liabilities | 3.88M | 5.89M | 183.11M | 37.05M | 3.17M |
| Non current liabilities | |||||
| Long term debt | 613.93M | 547.62M | 45.77M | 684.52M | 306.36M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 11.57M | 8.52M | 7.73M | 7.09M | 32.22M |
| Derivative product liabilities | 45.57M | 85.68M | — | 121.94M | 61,000 |
| Other non current liabilities | 128.63M | 131.14M | 136.74M | 147.47M | 129.72M |
| Shareholders equity | |||||
| Common stock | 82.53M | 82.42M | 82.30M | 76.30M | 76.26M |
| Retained earnings | -966.48M | -984.03M | -897.78M | -761.97M | -406.76M |
| Other shareholders equity | -27.88M | -48.12M | -7.18M | 27.81M | -19.39M |
| Total shareholders equity | 1.28B | 1.21B | 1.29B | 1.11B | 1.38B |
| Additional paid in capital | 2.19B | 2.16B | 2.12B | 1.77B | 1.73B |
| Treasury stock | 55,000 | 375,000 | 650,000 | 1.03M | 1.26M |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||||||
| Net Income | 17.55M | -86.25M | -135.82M | -348.82M | -157.64M | -189.40M | -25.09M | -62.79M | 57.85M | 54.89M | 46.36M | 36.08M | 46.73M | 78.45M | 26.72M | -10.33M | -51.18M | -59.07M | -18.61M | 4.62M | 5.18M | -26.12M | -3.93M | -12.50M | -14.20M | -11.20M | -10.10M | -7.20M | -5.90M | -5.10M |
| Depreciation | 60.86M | 57.80M | 67.99M | 81.32M | 82.99M | 69.94M | 82.94M | 85.36M | 6.81M | 5.63M | 4.64M | 4.70M | 3.29M | 2.60M | 2.18M | 3.96M | 4.49M | 4.49M | 10.38M | 7.06M | 5.12M | 4.30M | 1.45M | 1.50M | 700,000 | 300,000 | 200,000 | 300,000 | 300,000 | 200,000 |
| Deferred Taxes | -114.43M | 1.41M | 2.85M | 37.07M | -26.50M | -95.05M | -9.27M | -26.71M | 9.40M | -5.20M | 22.42M | 22.67M | 1.10M | -41.34M | 9,804 | -425,944 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 36.35M | 44.81M | 40.56M | 35.09M | 32.55M | 26.92M | 19.06M | 19.57M | 11.94M | 11.24M | 11.68M | 11.10M | 6.37M | 8.62M | 9.68M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Non-Cash Items | 29.52M | -6.89M | 17.94M | -8.75M | -21.42M | 2.22M | -16.91M | 48.57M | 14,000 | -1.33M | -1.49M | -1.49M | -1.49M | -1.52M | 4,361 | 11.41M | 19.47M | -232,752 | — | — | — | — | — | — | — | -100,000 | 100,000 | — | — | -200,000 |
| Accounts Receivable | -28.86M | -4.81M | -15.75M | 58.80M | -5.32M | 21.18M | -48.93M | -16.45M | -2.65M | -10.66M | -10.19M | -1.25M | -1.95M | -3.83M | -3.31M | -287,036 | 2.81M | -5.00M | 747,906 | -2.57M | -3.49M | -3.70M | -2.94M | 400,000 | -5.30M | -100,000 | -100,000 | -300,000 | -100,000 | — |
| Accounts Payable | 19.19M | -3.51M | 12.99M | -923,000 | -38.58M | 11.03M | 7.52M | 1.65M | — | 2.09M | 6.56M | 1.13M | -1.62M | 5.73M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Assets & Liabilities | -32.31M | -24.75M | 31.87M | -168.48M | -133.70M | 261.09M | -46.33M | -38.68M | -243,828 | -912,518 | 2.66M | 1.46M | -782,888 | -2.60M | -393,672 | 14.65M | 2.03M | -10.63M | -1.13M | -2.89M | -1.58M | -213,361 | -2.01M | -2.70M | -2.20M | -200,000 | -100,000 | -200,000 | -300,000 | -100,000 |
| Operating Cash Flow | -12.13M | -22.20M | 22.64M | -314.70M | -267.61M | 107.94M | -37.01M | 10.52M | 83.11M | 55.75M | 82.65M | 74.40M | 51.64M | 46.13M | 34.89M | 18.97M | -22.38M | -70.44M | -8.61M | 6.22M | 5.24M | -25.73M | -7.43M | -13.30M | -21.00M | -11.30M | -10.00M | -7.40M | -6.00M | -5.20M |
| Investing Activities | ||||||||||||||||||||||||||||||
| Capital Expenditures | -34.98M | -26.52M | -25.48M | -35.02M | -24.69M | -37.19M | -32.93M | -38.36M | -6.69M | -15.22M | -9.71M | -17.48M | -3.54M | -4.12M | -2.67M | -817,064 | -1.43M | -4.30M | -3.71M | -2.60M | -4.21M | -5.08M | -4.11M | -1.70M | -3.50M | -300,000 | -100,000 | -300,000 | -400,000 | -300,000 |
| Net Intangibles | — | — | — | — | -3.29M | -809,000 | -1.17M | -1.88M | — | -3.84M | -4.60M | -500,000 | -3.84M | -2.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | -8.86M | 41.25M | -1.72M | -10.75M | -93.01M | -14.19M | — | — | — | — | -4.00M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -6.50M | -2.95M | -3.65M | -3.18M | -2.50M | -3.77M | -6.26M | -15.08M | -33.17M | -45.34M | -21.59M | -4.00M | -5.00M | -100,000 | -250,000 | — | — | — | -10.40M | -16.30M | — | — | -52.53M | -46.00M | -75.20M | -11.60M | -3.20M | -8.10M | -15.50M | -15.90M |
| Sale of Investments | — | — | 23.06M | — | — | — | 3.19M | 14.05M | 30.09M | 29.99M | — | — | — | — | — | — | — | 22.80M | 2.50M | 1.40M | — | 1.79M | 55.06M | 61.10M | 44.10M | 4.40M | 6.10M | 18.90M | 17.60M | — |
| Investing Cash Flow | -40.33M | -38.41M | 36.90M | -41.84M | -41.29M | -119.75M | -51.68M | -44.52M | -9.77M | -30.57M | -31.39M | -25.48M | -7.54M | -4.22M | -2.92M | -817,064 | -1.43M | 17.50M | -11.61M | -17.50M | -4.21M | -3.29M | -1.59M | 13.40M | -34.60M | -7.50M | 2.80M | 10.60M | 1.70M | -16.20M |
| Financing Activities | ||||||||||||||||||||||||||||||
| Long-Term Debt Issuance | 50.00M | 507.55M | — | 886.90M | 197.16M | 103.57M | 2.05M | 7.23M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Long-Term Debt Payments | -23.60M | -223.54M | -487.85M | -526.90M | -24.21M | -314.57M | -22.76M | -54.82M | — | — | — | -7.04M | -8.24M | -43.05M | -50.40M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | -4.92M | -3.88M | -16.19M | -90.69M | -19.31M | -9.74M | -1.29M | -24.03M | 3.58M | 25.36M | 4.42M | — | — | — | — | -58,620 | -3,557 | — | — | — | — | — | — | — | — | — | — | — | -100,000 | 100,000 |
| Financing Cash Flow | 19.51M | 271.46M | -194.43M | 265.92M | 146.58M | -333.09M | 6.32M | -160.08M | -51.44M | -47.00M | -28.59M | -64.53M | -22.42M | -43.72M | -46.63M | 70,800 | 9.68M | 25.69M | 18.02M | 12.97M | 6.48M | 2.69M | 8.05M | 1.40M | 50.40M | 18.00M | 100,000 | 100,000 | 100,000 | 26.10M |
| Other Cash Details | ||||||||||||||||||||||||||||||
| End Cash Position | 577.87M | 515.62M | 207.99M | 252.83M | 61.14M | 47.20M | 93.62M | 39.79M | 124.19M | 103.30M | 120.71M | 96.65M | 89.31M | 59.23M | 66.23M | 91.06M | 84.80M | 92.36M | 38.68M | 43.46M | 43.58M | 38.20M | 14.97M | 1.60M | — | 800,000 | — | — | — | — |
| Income Tax Paid | — | 1.22M | — | 7.49M | 2.01M | 26.39M | 38.97M | 47.81M | 15.58M | 4.30M | 3.52M | 1.12M | 1.28M | 1.07M | 686,634 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | 36.91M | 19.04M | 32.57M | 28.57M | 15.83M | 9.28M | 7.51M | 7.37M | 1,000 | 4,000 | 96,000 | 281,206 | 372,939 | 1.32M | 3.02M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Free Cash Flow | 39.93M | 43.40M | 77.07M | -114.45M | -115.83M | 82.49M | 57.23M | 51.79M | 72.99M | 35.14M | 64.75M | 57.04M | 42.49M | 36.76M | 21.92M | 13.64M | -22.11M | -75.18M | -7.68M | 994,757 | -2.93M | -28.13M | -12.29M | -16.40M | -18.30M | -12.30M | -9.70M | -6.60M | -6.00M | -5.10M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Horizon Fund-Capital Opportunity Fund | Sep 30, 2024 | 1,968,900 | 95.00M | 3.63% |
| iShares Core S&P Midcap ETF | Nov 30, 2024 | 1,743,859 | 84.14M | 3.21% |
| iShares Russell 2000 ETF | Nov 30, 2024 | 1,529,854 | 73.82M | 2.82% |
| Smallcap World Fund | Sep 30, 2024 | 1,243,231 | 59.99M | 2.29% |
| Primecap Odyssey Aggressive Growth Fund | Oct 31, 2024 | 1,030,140 | 49.70M | 1.90% |
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 818,897 | 39.51M | 1.51% |
| Vanguard Fenway Fds-Primecap Core Fund | Sep 30, 2024 | 800,200 | 38.61M | 1.47% |
| Primecap Odyssey Growth Fund | Oct 31, 2024 | 798,500 | 38.53M | 1.47% |
| Fidelity Small Cap Index Fund | Oct 31, 2024 | 556,641 | 26.86M | 1.03% |
| iShares Russell 2000 Value ETF | Nov 30, 2024 | 502,425 | 24.24M | 0.93% |
Article
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to rec.
Jan 21, 2025
Article
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
Dec 30, 2024
Article
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.
Dec 18, 2024
